Beijing Wantai's Subsidiary Files for WHO Prequalification of Its Self-Developed 9-Valent HPV Vaccine

Stock News06-01

Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SHA: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., recently submitted the application dossier for World Health Organization (WHO) Prequalification (PQ) of its independently developed 9-valent human papillomavirus (HPV) vaccine (Escherichia coli).

This 9-valent HPV vaccine is a preventive biological product developed by Wantai Canghai. It obtained a drug registration certificate from China's National Medical Products Administration in 2025, marking it as China's first and the world's second 9-valent HPV vaccine.

The vaccine is primarily indicated for females aged 9 to 45, covering seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), and is designed to prevent related diseases caused by infection from these HPV types.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122657388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122657388","market":"sg","top_or_hot":-1,"title":"Beijing Wantai's Subsidiary Files for WHO Prequalification of Its Self-Developed 9-Valent HPV Vaccine","media":"Stock News","content":"<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SHA: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., recently submitted the application dossier for World Health Organization (WHO) Prequalification (PQ) of its independently developed 9-valent human papillomavirus (HPV) vaccine (Escherichia coli).<br><br>This 9-valent HPV vaccine is a preventive biological product developed by Wantai Canghai. It obtained a drug registration certificate from China's National Medical Products Administration in 2025, marking it as China's first and the world's second 9-valent HPV vaccine.<br><br>The vaccine is primarily indicated for females aged 9 to 45, covering seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), and is designed to prevent related diseases caused by infection from these HPV types.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Wantai's Subsidiary Files for WHO Prequalification of Its Self-Developed 9-Valent HPV Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Wantai's Subsidiary Files for WHO Prequalification of Its Self-Developed 9-Valent HPV Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SHA: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., recently submitted the application dossier for World Health Organization (WHO) Prequalification (PQ) of its independently developed 9-valent human papillomavirus (HPV) vaccine (Escherichia coli).<br><br>This 9-valent HPV vaccine is a preventive biological product developed by Wantai Canghai. It obtained a drug registration certificate from China's National Medical Products Administration in 2025, marking it as China's first and the world's second 9-valent HPV vaccine.<br><br>The vaccine is primarily indicated for females aged 9 to 45, covering seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), and is designed to prevent related diseases caused by infection from these HPV types.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1200","symbol_name":"软饮料","start_time":0,"source_url":"","article_id":"1122657388","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122657388","pubTimestamp":1780302864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SHA: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., recently submitted the application...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","603392":"万泰生物","BK1200":"软饮料","09633":"农夫山泉","BK0239":"医药制造","BK1589":"北水核心资产","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC"},"translate_title":"北京万泰子公司自研9价HPV疫苗申请WHO资格预审","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"603392":1,"09633":1},"content_text":"Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (SHA: 603392) has announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., recently submitted the application dossier for World Health Organization (WHO) Prequalification (PQ) of its independently developed 9-valent human papillomavirus (HPV) vaccine (Escherichia coli).This 9-valent HPV vaccine is a preventive biological product developed by Wantai Canghai. It obtained a drug registration certificate from China's National Medical Products Administration in 2025, marking it as China's first and the world's second 9-valent HPV vaccine.The vaccine is primarily indicated for females aged 9 to 45, covering seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), and is designed to prevent related diseases caused by infection from these HPV types.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122657388","isCrawlerRequest":true}